ClinicalTrials.gg

Coronary Disease clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,521 studies for Coronary Disease across more than 10 countries. 167 are recruiting or about to start. 829 of them are mainly about Coronary Disease (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 8 narrower conditions too, such as Coronary Artery Disease: 6,381 studies, 1,068 open.

ClinicalTrials.gov finds 34,178 studies for Coronary Disease. How that becomes 1,521 here

This page counts the studies the registry files under Coronary Disease, and those it files under no condition that list Coronary Diseasethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 34,178Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −4,794Filed under a narrower condition, counted on its own pageCoronary Artery Disease 4,447 · Coronary Stenosis 125 · Coronary Restenosis 31 · Coronary Occlusion 28 · Coronary Aneurysm 25 · Coronary Vasospasm 20 · 2 more
  3. −22List Coronary Disease as a condition, but the registry did not file them under itMost often written as “Coronary Heart Disease Risk Reduction” (8), “Coronary Heart Disease NOS” (2), and “Non-obstructive Coronary Disease” (2). The registry filed them under other conditions only, most often Cardiovascular Diseases (9) and Heart Diseases (8).
  4. −27,841Match it another way131 name it in the title, 12 in a keyword, and 27,698 by a synonym or other text the search reads.
  5. 1,521The count on this page20 of them list Coronary Disease in their own words; the registry filed them under no condition.

Status

Completed
993
Status unknown
215
Recruiting
105
Active, not recruiting
59
Not yet recruiting
52
Terminated
49

Phase

Phase 4
162
Phase 3
156
Phase 2
100
Phase 1
32
Early Phase 1
9

Where

United States
274
China
223
Germany
123
United Kingdom
91
Canada
75
Italy
58

Who develops what

Add Coronary Disease to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 3 programs from 3 companies, 2 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months. Compare Amgen and Novartis here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
SimvastatinEarlier only
Evidence
  • NCT00654407 · AstraZeneca · Phase 3 · comparator · “Simvastatin” · registered Apr 2008
  • NCT00344175 · Kowa Company, Ltd. · Phase 3 · comparator · “simvastatin” · registered Jun 2006
  • NCT00120289 · axio research llc · Phase 3 · background · “Simvastatin” · registered Jul 2005
Organon & Co.29% of its industry studiesUS: off-patent, 10 generics marketed00 studies
AtorvastatinEarlier only
Evidence
  • NCT00654407 · AstraZeneca · Phase 3 · comparator · “Atorvastatin” · registered Apr 2008
  • NCT00653588 · AstraZeneca · Phase 3 · comparator · “Atorvastatin” · registered Apr 2008
  • NCT00639158 · Abbott · Phase 3 · background · “atorvastatin” · registered Mar 2008
Viatris Inc.16% of its industry studiesUS: off-patent, 23 generics marketed00 studies
EzetimibeEarlier only
Evidence
  • NCT00653445 · AstraZeneca · Phase 3 · background · “Ezetimibe” · registered Apr 2008
  • NCT00639158 · Abbott · Phase 3 · background · “ezetimibe” · registered Mar 2008
Organon & Co.59% of its industry studiesUS: off-patent, 14 generics marketed00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 3 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Apr 2027 est.inclisiran · Novartis · Phase 4 main aimNCT06941792 Inclisiran Effectiveness in China: a Pragmatic Randomized Trial — primary endpoint: The percentage change in low-density lipoprotein cholesterol (LDL-C) level from baseline at 12 months, for the inclisiran group versus the standard of care (SoC) group · 1,590 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Coronary Disease studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here P2Y12 inhibitors 1 open · Statins 34 · NSAIDs 11 · ACE inhibitors 6 · Estrogens 4

Coming up

54studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 105 Coronary Disease studies recruiting now, 63 (60%) set no upper age limit and 19 (18%) stop at 75 or younger. 8 (8%) take children under 18. 3 (3%) are for women only and 0 (0%) for men only; 10 (10%) take healthy volunteers.

Recruiting studies that take each age, of 105
AgeWomenMen
108 (8%)8 (8%)
1878 (74%)76 (72%)
3087 (83%)85 (81%)
4090 (86%)88 (84%)
5094 (90%)91 (87%)
6598 (93%)95 (90%)
7595 (90%)93 (89%)
8575 (71%)74 (70%)

Across all 1,521 studies, recruiting or not: 20% stop at 75 or younger and 6% at 65; 18% take children; 3% are for women only and 10% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Coronary Disease studies take

Of 26 phase 4 interventional studies under Coronary Disease, half reached primary completion within 33 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 217 mo10–39 · 19 studies——
Phase 433 mo16–58 · 26 studies——
Interventional, no phase25 mo14–51 · 200 studies—26 mo15–51 · 178 studies
Observational47 mo21–123 · 154 studies—59 mo24–192 · 132 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,521. Browse all 1,521 → or search them.